CagriSema (CagriSema (Cagrilintide + Semaglutide))
A fixed-ratio combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) targeting complementary appetite pathways for enhanced weight loss.
How it works
Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression.
Key facts
- Molecular weight: Combination product
- Half-life: 7 days (both components)
- Bioavailability: High (SubQ)
- Storage: Refrigerated 2-8°C.
Dosing overview
- Typical dose: Cagrilintide 2.4mg + Semaglutide 2.4mg
- Frequency: Once weekly
- Duration: Ongoing
- Route: Subcutaneous
Reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Possible side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Injection site reactions
Research
- Phase 2 CagriSema combination for obesity (2023): CagriSema achieved 15.6% weight loss at 32 weeks vs 5.1% cagrilintide alone and 8.1% semaglutide alone.
- Amylin-GLP-1 combination approaches (2022): Dual-pathway targeting showed additive appetite suppression in neuroimaging studies.
Compare CagriSema
Community discussions about CagriSema
- Observations on CagriSema satiety versus semaglutide monotherapy - 4 comments
- Semaglutide appetite stalled at 1mg, anyone else hit this wall? - 6 comments
- CagriSema vs AOD-9604 for weight loss - 4 comments
- CagriSema experience – weight change and side effects after 8 weeks - 8 comments
- My 6‑week CagriSema titration: appetite dip, nausea spikes and a weird HRV bump - 4 comments
- Ask the community about CagriSema
Research and educational reference only. Not medical advice.